Literature DB >> 25257871

Effect of inhaled terbutaline on substrate utilization and 300-kcal time trial performance.

Anders Kalsen1, Morten Hostrup2, Sebastian Karlsson3, Peter Hemmersbach4, Jens Bangsbo5, Vibeke Backer3.   

Abstract

In a randomized, double-blind crossover design, we investigated the effect of the beta2-agonist terbutaline (TER) on endurance performance and substrate utilization in nine moderately trained men [maximum oxygen uptake (V̇O(2 max)) 58.9 ± 3.1 ml·min(-1)·kg(-1)]. Subjects performed 60 min of submaximal exercise (65-70% of V̇O(2 max)) immediately followed by a 300-kcal time trial with inhalation of either 15 mg of TER or placebo (PLA). Pulmonary gas exchange was measured during the submaximal exercise, and muscle biopsies were collected before and after the exercise bouts. Time trial performance was not different between TER and PLA (1,072 ± 145 vs. 1,054 ± 125 s). During the submaximal exercise, respiratory exchange ratio, glycogen breakdown (TER 266 ± 32, PLA 195 ± 28 mmol/kg dw), and muscle lactate accumulation (TER 20.3 ± 1.6, PLA 13.2 ± 1.2 mmol/kg dw) were higher (P < 0.05) with TER than PLA. There was no difference between TER and PLA in net muscle glycogen utilization or lactate accumulation during the time trial. Intramyocellular triacylglycerol content did not change with treatment or exercise. Pyruvate dehydrogenase-E1α phosphorylation at Ser(293) and Ser(300) was lower (P < 0.05) before submaximal exercise with TER than PLA, with no difference after the submaximal exercise and the time trial. Before submaximal exercise, acetyl-CoA carboxylase 2 (ACC2) phosphorylation at Ser(221) was higher (P < 0.05) with TER than PLA. There was no difference in phosphorylation of alpha 5'-AMP-activated protein kinase (αAMPK) at Thr(172) between treatments. The present study suggests that beta2-agonists do not enhance 300-kcal time trial performance, but they increase carbohydrate metabolism in skeletal muscles during submaximal exercise independent of AMPK and ACC phosphorylation, and that this effect diminishes as drug exposure time, exercise duration, and intensity are increased.
Copyright © 2014 the American Physiological Society.

Entities:  

Keywords:  exercise performance; substrate utilization; terbutaline

Mesh:

Substances:

Year:  2014        PMID: 25257871     DOI: 10.1152/japplphysiol.00635.2014

Source DB:  PubMed          Journal:  J Appl Physiol (1985)        ISSN: 0161-7567


  5 in total

1.  Beta2-adrenergic stimulation increases energy expenditure at rest, but not during submaximal exercise in active overweight men.

Authors:  Johan Onslev; Glenn Jacobson; Christian Narkowicz; Vibeke Backer; Anders Kalsen; Michael Kreiberg; Søren Jessen; Jens Bangsbo; Morten Hostrup
Journal:  Eur J Appl Physiol       Date:  2017-07-12       Impact factor: 3.078

2.  β2-adrenergic stimulation enhances Ca2+ release and contractile properties of skeletal muscles, and counteracts exercise-induced reductions in Na+-K+-ATPase Vmax in trained men.

Authors:  M Hostrup; A Kalsen; N Ortenblad; C Juel; K Mørch; S Rzeppa; S Karlsson; V Backer; J Bangsbo
Journal:  J Physiol       Date:  2014-10-24       Impact factor: 5.182

3.  Chronic β2 -adrenoceptor agonist treatment alters muscle proteome and functional adaptations induced by high intensity training in young men.

Authors:  Morten Hostrup; Johan Onslev; Glenn A Jacobson; Richard Wilson; Jens Bangsbo
Journal:  J Physiol       Date:  2017-11-12       Impact factor: 5.182

Review 4.  The World Anti-Doping Code: can you have asthma and still be an elite athlete?

Authors:  Ken Fitch
Journal:  Breathe (Sheff)       Date:  2016-06

5.  Effects of Terbutaline Sulfate on Physiological and Biomechanical as Well as Perceived Exertion in Healthy Active Athletes: A Pilot Study.

Authors:  Hanen Hafedh; Maamer Slimani; Bianca Miarka; Ramzi Bettayeb; Nicola Luigi Bragazzi
Journal:  J Hum Kinet       Date:  2019-10-18       Impact factor: 2.193

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.